Kazuhito Kawata

Hamamatsu, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 195 publications

Reply to "Did the COVID-19 pandemic disrupt the continuity of post-SVR surveillance in HCV-cured patients?"

Reply to "Did the COVID-19 pandemic disrupt the continuity of post-SVR surveillance in HCV-cured patients?"

Journal: Journal of gastroenterology

Published: August 17, 2026

Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 29, 2026

Metabolomics Approach Identifies Predictive Serum Markers for Hepatocellular Carcinogenesis Following Hepatitis C Virus Elimination.

Metabolomics Approach Identifies Predictive Serum Markers for Hepatocellular Carcinogenesis Following Hepatitis C Virus Elimination.

Journal: Cancers

Published: April 28, 2026

Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

Journal: Oncology

Published: April 19, 2026

The Impact of Antithrombotic Therapy on Bleeding Complications in Percutaneous Liver Biopsy: Are the Withdrawal Criteria of Antithrombotic Agents in Japan Gastroenterological Endoscopy Society Guidelines for Gastroenterological Endoscopy Useful?

The Impact of Antithrombotic Therapy on Bleeding Complications in Percutaneous Liver Biopsy: Are the Withdrawal Criteria of Antithrombotic Agents in Japan Gastroenterological Endoscopy Society Guidelines for Gastroenterological Endoscopy Useful?

Journal: Diseases (Basel, Switzerland)

Published: April 18, 2026

Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: April 07, 2026

Mac-2 binding protein glycosylation isomer contributes to identify advanced Fontan-associated liver disease: A retrospective cohort study.

Mac-2 binding protein glycosylation isomer contributes to identify advanced Fontan-associated liver disease: A retrospective cohort study.

Journal: Medicine

Published: March 17, 2026

Stability and Variability of Symptom Burden in Primary Biliary Cholangitis: Insights From a Decade of Follow-Up.

Stability and Variability of Symptom Burden in Primary Biliary Cholangitis: Insights From a Decade of Follow-Up.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: March 04, 2026

Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine-cisplatin in advanced biliary tract cancer: a multicenter real-world study.

Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine-cisplatin in advanced biliary tract cancer: a multicenter real-world study.

Journal: Journal of gastroenterology

Published: February 20, 2026

Association between pretherapeutic M2BPGi levels and postoperative skeletal muscle depletion in patients with esophageal squamous cell carcinoma.

Association between pretherapeutic M2BPGi levels and postoperative skeletal muscle depletion in patients with esophageal squamous cell carcinoma.

Journal: Esophagus : official journal of the Japan Esophageal Society

Published: February 10, 2026

Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study.

Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study.

Journal: Hepatology (Baltimore, Md.)

Published: January 27, 2026

Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

Journal: Journal of gastroenterology and hepatology

Published: January 19, 2026

Showing 1-12 of 195

Last Updated: 09/26/2026